Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Diltiazem hydrochloride
Kent Pharma (UK) Ltd
C08DB01
Diltiazem hydrochloride
120mg
Modified-release capsule
Oral
No Controlled Drug Status
Caution - AMP level prescribing advised
BNF: 02060200; GTIN: 5015201006206
PATIENT INFORMATION LEAFLET (diltiazem hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. • KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. • IF YOU HAVE FURTHER QUESTIONS, PLEASE ASK YOUR DOCTOR OR YOUR PHARMACIST. • THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. DO NOT PASS IT ON TO OTHERS. IT MAY HARM THEM, EVEN IF THEIR SYMPTOMS ARE THE SAME AS YOURS. • IF YOU GET ANY SIDE EFFECTS, TALK TO YOUR DOCTOR OR PHARMACIST. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS NOT LISTED IN THIS LEAFLET. SEE SECTION 4 PREGNANCY, BREAST-FEEDING AND FERTILITY DO NOT take this medicine if you: • are pregnant or planning to become pregnant Like all medicines, this medicine can cause side effects, although not everybody gets them. STOP TAKING YOUR MEDICINE AND TELL YOUR DOCTOR IMMEDIATELY, OR GO TO YOUR NEAREST HOSPITAL CASUALTY DEPARTMENT IF YOU EXPERIENCE: • an allergic reaction. The symptoms may include a rash, problems with swallowing or breathing, swelling of the lips, face, throat or tongue • severe blistering rash where layers of skin peel off leaving scalded skin. You may also have a fever. This could be an illness called ‘toxic epidermal necrolysis’. • a skin rash with dark circles and pale centres, red patches, blistering or peeling. You may also have a fever. This could be an illness called ‘erythema multiforme’ or ‘Stevens-Johnson syndrome’. • heart problems or heart failure. The signs could be shortness of breath, flushing, feeling of tiredness along with swollen ankles and legs • a severe slowing of the heart (which may cause either fainting or dizziness) • hepatitis (symptoms include high temperature, nausea, muscle aches, tiredness, loss of appetite and diarrhoea). A disturbance in liver enzyme level is often detectable by a blood test. WHAT KENZEM SR CAPSULES CONTAIN Kenzem 60mg, 90mg or 120mg SR Capsules contain the active ingredient diltiazem hydrochloride. The other inactive ingredients include sugar spheres (sucrose and maize starch), povidone, m Read the complete document
OBJECT 1 KENZEM 120MG SR CAPSULES Summary of Product Characteristics Updated 16-Jan-2017 | Kent Pharmaceuticals Ltd • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • Administrative data • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Kenzem 120mg SR Capsules 2. Qualitative and quantitative composition Each capsule contains 120mg of diltiazem hydrochloride Excipients with known effect: Product contains sucrose. For full list of excipients, see section 6.1 3. Pharmaceutical form Modified release capsule 4. Clinical particulars 4.1 Therapeutic indications The treatment of angina pectoris. The treatment of mild to moderate hypertension. 4.2 Posology and method of administration Kenzem (Diltiazem hydrochloride) is available in a range of presentations to enable dosage to be adjusted to meet individual requirements of the patient. Careful titration of the dose should be considered where appropriate, as individual patient response may vary. When changing from one type of diltiazem formulation to another it may be necessary Read the complete document